Belimumab becomes first FDA-approved drug for pediatric lupus nephritis

The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
The announcement makes belimumab (Benlysta, GlaxoSmithKline) the first FDA-approved treatment for pediatric lupus nephritis, the release said. The new indication includes children aged 5 to 17 years.
“Active lupus nephritis is a potential serious complication in children with lupus, with most cases occurring within the first 2 years after their initial lupus diagnosis,” Stevan W. Gibson,

The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
The announcement makes belimumab (Benlysta, GlaxoSmithKline) the first FDA-approved treatment for pediatric lupus nephritis, the release said. The new indication includes children aged 5 to 17 years.
“Active lupus nephritis is a potential serious complication in children with lupus, with most cases occurring within the first 2 years after their initial lupus diagnosis,” Stevan W. Gibson,